Both p53-PUMA/NOXA-Bax-mitochondrion and p53-p21cip1 pathways are involved in the CDglyTK-mediated tumor cell suppression

Biochemical and Biophysical Research Communications

Volumn 386, Issue 4, 2009, Pages 607-611

  Yu, Zhendong ^a   Wang, Hao ^b   Zhang, Libin ^a   Tang, Aifa ^a   Zhai, Qinna ^a   Wen, Jianxiang ^a   Yao, Li ^a   Li, Pengfei ^b  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bax; Bcl2; CDglyTK; Gene therapy; Nasopharyngeal carcinoma (NPC); NOXA; p21; p53; PUMA

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOSINE DEAMINASE GLYCINE THYMIDINE KINASE FUSION PROTEIN; FLUCYTOSINE; GANCICLOVIR; MITOCHONDRIAL PROTEIN; PROTEIN BAX; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; FUSION GENE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; WILD TYPE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; MITOCHONDRIA; NEOPLASMS; PRODRUGS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; THYMIDINE KINASE; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE;

EID: 67650498350     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.083     Document Type: Article

References (25)

1. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46 (1986) 5276-5281
2. Mullen C.A., Kilstrup M., and Blaese R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89 (1992) 33-37
3. Daher G.C., Harris B.E., and Diasio R.B. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol. Ther. 48 (1990) 189-222
4. Rogulski K.R., Kim J.H., Kim S.H., and Freytag S.O. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. 8 (1997) 73-85
5. Xia K., Liang D., Tang A., Feng Y., Zhang J., Pan Q., Long Z., Dai H., Cai F., Wu L., Zhao S., Chen Z., and Xia J. A novel fusion suicide gene yeast CDglyTK plays a role in radio-gene therapy of nasopharyngeal carcinoma. Cancer Gene Ther. 11 (2004) 790-796
6. Fillat C., Carrio M., Cascante A., and Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr. Gene Ther. 3 (2003) 13-26
7. Gopinath P., and Ghosh S.S. Understanding apoptotic signaling pathways in cytosine deaminase-uracil phosphoribosyl transferase-mediated suicide gene therapy in vitro. Mol. Cell. Biochem. 324 (2009) 21-29
8. Bode A.M., and Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4 (2004) 793-805
9. El-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., Pietenpol J.A., Burrell M., Hill D.E., Wang Y., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54 (1994) 1169-1174
10. Jin S., Tong T., Fan W., Fan F., Antinore M.J., Zhu X., Mazzacurati L., Li X., Petrik K.L., Rajasekaran B., Wu M., and Zhan Q. GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene 21 (2002) 8696-8704
11. Hermeking H., and Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin. Cancer Biol. 16 (2006) 183-192
12. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., and Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404 (2000) 42-49
13. Takimoto R., MacLachlan T.K., Dicker D.T., Niitsu Y., Mori T., and El-Deiry W.S. BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol. Ther. 1 (2002) 177-186
14. Burns T.F., and El-Deiry W.S. The p53 pathway and apoptosis. J. Cell. Physiol. 181 (1999) 231-239
15. Sax J.K., and El-Deiry W.S. p53 downstream targets and chemosensitivity. Cell Death Differ. 10 (2003) 413-417
16. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., and Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
17. Yu J., Wang Z., Kinzler K.W., Vogelstein B., and Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 1931-1936
18. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., and Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (2000) 1053-1058
19. Lee A.W., Li J.H., Shi W., Li A., Ng E., Liu T.J., Klamut H.J., and Liu F.F. P16 gene therapy: a potentially efficacious modality for nasopharyngeal carcinoma. Mol. Cancer Ther. 2 (2003) 961-969
20. Yang H., Zhao R., and Lee M.H. 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Mol. Cancer Ther. 5 (2006) 253-260
21. Corban-Wilhelm H., Becker G., Bauder-Wust U., Greulich D., and Debus J. Cytosine deaminase versus thymidine kinase: a comparison of the antitumor activity. Clin. Exp. Med. 3 (2003) 150-156
22. Efeyan A., and Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 6 (2007) 1006-1010
23. Blandino G., Levine A.J., and Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18 (1999) 477-485
24. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., and Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104 (1999) 263-269
25. Fischer U., Steffens S., Frank S., Rainov N.G., Schulze-Osthoff K., and Kramm C.M. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene 24 (2005) 1231-1243